Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Your trusted source for the latest news delivered weekdays from the team at U.S. News and World Report. Sign in to manage your newsletters » Sign up to receive the latest updates from U.S News ...

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be ...

Add galleries to your saved list and come back to them any time.

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

This advertisement has not loaded yet, but your article continues below.

The European Commission has become the first regulator worldwide to approve Sanofi and Regeneron’s IL-4 and IL-13 inhibitor Dupixent (dupilumab) as a treatment for the progressive lung disease ...

This advertisement has not loaded yet, but your article continues below.

Bill Bramhall's editorial cartoon for Friday, Aug. 4, 2023, shows the defense saying, "It's not ...

The news of the day as interpreted by our talented artists, illustrators and cartoonists.

Michael Ramirez cartoon on Donald Trump’s messy policies.